How to evaluate venture capital term sheets before you sign away your company
Two offers land in the same week. One leads with a $14M pre-money valuation. The other says $10M. Any founder I know grabs the first one. And roughly half of them will regret it, because the term sheet that looks smaller often pays out more at exit once you actually run the math on the non-valuation clauses.
I've watched this play out on both sides of the table. Valuation is the number everyone negotiates over dinner. It is also the number that matters least in the fine print.
Key takeaways
- Valuation is the headline; liquidation preference and participation decide what you actually take home.
- A 1x non-participating preference is the founder-friendly baseline. Participating preferred with a 2x multiple can wipe out your common stock in a modest exit.
- Board composition matters more the longer you hold the company. Two investor seats out of three hands over control.
- Build a weighted scorecard and rank every offer side by side. Gut feeling loses to a spreadsheet here.
- Watch the no-shop clause: it freezes your fundraising for weeks.
- A good lawyer pays for itself in a single clause correction. Get one before you respond to anything.
Why a weighted scorecard beats your gut
Most founders evaluate a term sheet the way they'd evaluate a job offer: salary first, everything else a blur. That instinct fails badly with venture deals, because the individual clauses interact. A generous valuation paired with a 2x participating preference is a worse deal than a modest valuation with a clean 1x non-participating structure. You can't see that by reading the terms one at a time.
So I score them. Four buckets, each weighted by how much it affects your outcome:
- Economics (40%) — valuation, preference multiple, participation, option pool size, anti-dilution type.
- Control (30%) — board seats, protective provisions, voting rights, consent thresholds.
- Liquidity and exit (20%) — drag-along, redemption rights, tag-along, IPO ratchets.
- Relationship and track record (10%) — but not because it's unimportant. Because it's the hardest to score objectively and the easiest to regret ignoring.
How to score the economics bucket
Take a clean exit scenario. Say you sell for $30M. You raised $10M at a $20M post-money valuation, so the investor owns 50%.
Under a 1x non-participating preference, the investor chooses: take $10M back, or convert to common and take 50% of $30M — which is $15M. They convert. You split the rest, and you net $15M.
Under a 2x participating preference, the investor takes $20M off the top (2x their money), then participates pro-rata in what's left. That's $20M plus half of the remaining $10M — $25M to them, $5M to you and everyone else on the cap table.
Same exit. Same valuation. Your payout drops from $15M to $5M. That's the whole argument for scoring economics rather than admiring the headline number. Run this math on every offer before you compare anything else.
| Clause | Founder-friendly | Investor-friendly | Weight |
|---|---|---|---|
| Liquidation preference | 1x non-participating | 2x+ participating | High |
| Board seats | Founder majority (2 of 3) | Investor control (2 of 3) | High |
| Option pool | Post-money, 10–12% | Pre-money, 20%+ | Medium |
| Anti-dilution | Broad-based weighted average | Full ratchet | Medium |
| No-shop period | 30 days or less | 60+ days, exclusive | Low |
| Redemption rights | None | Forced buyback triggers | Medium |
The control clauses founders consistently miss
Board seats get negotiated last, usually when everyone is tired. That's a mistake. The board hires and fires the CEO. It approves budgets, new rounds, and acquisitions. If your investor holds two of three seats, you work for them — regardless of what your equity stake says.
The subtler version is protective provisions. These are veto rights over specific actions: raising a new round, selling the company, changing the business model, issuing new shares. A short list is normal and reasonable. A long list turns every strategic decision into a negotiation with your investor.
Count them. If the list runs past a dozen items, you've handed over operational control in installments. And here's the thing most founders don't realize until it's too late: the vetoes are enforced by the same people who sit on your board, so you're negotiating with yourself.
What does a "no-shop" clause actually cost you?
It costs you time, and time has a price. The no-shop clause stops you from talking to other investors for a set period while the lead investor completes diligence. Thirty days is standard. Sixty days is aggressive. Ninety days is a red flag, because it signals the investor expects problems and wants you locked in while they dig.
During that window, competing offers evaporate. Your leverage disappears. So the number matters: the longer the exclusivity, the more you should scrutinize everything else in the document. I've seen a founder lose a better offer because a 75-day no-shop expired two days before the second term sheet arrived. He signed the first one.
How to compare term sheets from several investors at once
Syndication complicates the picture. When there's a lead investor and followers, you're not evaluating one term sheet. You're evaluating whether the group holds together.
The lead sets the terms. Followers piggyback. That's fine until you hit a consent or majority threshold buried in the document. If a strategic decision requires approval from holders of a majority of the preferred, and the lead holds a slim majority of the preferred, the followers are decorative. If the lead holds less than half, you may end up needing to negotiate with three parties who don't agree with each other.
Ask directly: who decides, and at what threshold? Get it in writing before the definitive agreements.
Non-financial signals worth scoring
Some of the most expensive terms in the document aren't terms at all. They're behaviors you can only assess by looking at the investor's history.
- How did they treat founders in down rounds? Did they lead or did they sit out?
- Do they take board seats and disappear, or do they actually open doors? Ask for two founder references from portfolio companies that went through a rough patch, not the ones that exited well.
- What's their reserve strategy? A fund with no reserves for follow-on means you're raising again with someone who can't protect their position — and won't protect yours.
I once compared two offers where the smaller fund offered half the money but three times the operational support. The founder took the bigger check. Eighteen months later he was raising a bridge from the same investor who'd already declined to follow on. That reservation showed up in the term sheet's silence.
A step-by-step process you can run in two weeks
Here's the sequence that keeps you from signing something you'll regret:
- Day 1–2: Send every term sheet to your lawyer before you respond to anyone. Do not negotiate in email threads you'll later regret.
- Day 3: Score each offer against the weighted matrix. Fill in real numbers, not adjectives.
- Day 4–5: Rank them. Then identify your two must-have corrections — the clauses you'll walk away over. Two, not ten.
- Day 6–10: Negotiate the top two, concede the small stuff. Founders who fight over everything lose credibility on the things that matter.
- Day 11–14: Confirm the no-shop window, then sign and move to diligence.
Two weeks is realistic if you have a lawyer lined up in advance. If you don't, you'll spend the first week finding one, and the no-shop clock is already running.
What documents do you need to actually read?
The term sheet itself, plus the definitive agreements that follow. The term sheet is mostly non-binding — with a few exceptions that are binding, usually confidentiality, exclusivity, and any governing-law provisions. Those exceptions are where deals get stuck, so read them carefully even though they look like boilerplate.
Is a term sheet legally binding?
Largely no. Most of it is a statement of intent, and either side can walk away before the definitive agreements are signed. The binding parts are typically the confidentiality clause, the no-shop or exclusivity clause, and sometimes expense reimbursement if the deal collapses. Everything else — valuation, preferences, board seats — is a promise the definitive documents formalize later. Which is precisely why you negotiate hard now: this is your last moment of real leverage before diligence starts and the cost of walking away becomes enormous.
The number that should decide it
Here's the test I'd put to any founder holding two offers: don't compare valuations. Compare what you take home in the median exit for your sector — the one that isn't a home run. Run the preference math on a $25M sale, a $50M sale, and a $100M sale. The offer that wins in the middle is usually the offer that wins everywhere else.
The best term sheet I ever saw wasn't the one with the highest number on it. It was the one where, on a bad day, the founder still kept the company. That's the clause nobody puts in the headline, and the only one you'll remember five years from now.
